Chemotherapy Induced Nausea and Vomiting Prophylaxis in High-Dose Melphalan and Autologous Stem Cell Transplantation

We have read with great interest the paper by Trifilio S. and colleagues1, entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study”. The authors illustrated the result of a retrospective comparative clinical trial of olanzapine-contain ing regimen versus aprepitant or fosaprepitant-containing regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT) with high dose melphalan (HDMel).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research

Related Links:

ConclusionMesenteric involvement of DLBCL can be successfully targeted with localized ISRT fields using IMRT and daily CT-image guidance.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xianrui Zhang, Meiyun FangAbstractTEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. The etiology and pathophysiology of this condition remains elusive. Nevertheless, clonal plasma cells and monoclonal protein appear to be major contributors. The early diagnosis of TEMPI syndrome is essential b...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu KandaAbstractBackgroundWT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Wasithep Limvorapitak, Michael Barnett, Donna Hogge, Donna Forrest, Thomas Nevill, Sujaatha Narayanan, Maryse Power, Stephen Nantel, Raewyn Broady, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, Alina Gerrie, Jennifer White, David SanfordAbstract (245 word of 250 words recommended)IntroductionOptimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia (AML) remains an area of ongoing research. We aimed to retrospectively compare outcomes following autoSCT with allogeneic SCT (allo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Survival of adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal as they are often resistant to multiple salvage chemotherapy regimens. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products, are changing the landscape of B-cell (B)-ALL, but little progress has been made in R/R T-cell (T)-ALL.1-4 Allogenic stem cell transplantation (allo-SCT) is the only potentially curative option but requires achievement of complete remission (CR) before transplant.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Nicholas J. Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias JabbourAbstractThe widespread adoption of Bcr–Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of 
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions: 18F-FDG PET / CT helps to make FL patient’s treatment decisions by suggesting histological large cell transformation, clarifying clinical staging and finding treatment indications.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusion: In patients with relapsing or refractory DLBCL treated with R-DHAC salvage therapy followed by ASCT, pre-transplant 18-FDG PET/CT SUVmax and whole-body TLG remains the strongest predictive factors of PFS and OS. While a Deauville score of 5 also carries a dismal prognosis, a Deauville score of 4 does not appear to preclude a successful ASCT.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusion: The significant decrease in GSUVmean and GSUVmax of the MM patients in the HDT group seems to indicate that the aggressive treatment in these patients was successful in decreasing the number of myeloma lesions and possibly decreasing the incidence of insufficiency fractures, which can augment the uptake of NaF. Furthermore, chemotherapy can decrease the uptake of NaF, and as a result, high dose chemotherapy could have directly caused lower uptake of NaF. Further studies involving larger samples are needed to confirm our findings.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
More News: Chemotherapy | Clinical Trials | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants | Zyprexa